Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
Public ClinicalTrials.gov record NCT00366106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open Label Study Evaluating an Alternative Schedule of Velcade/Dexamethasone Plus Doxil in the Treatment of Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.
Study identification
- NCT ID
- NCT00366106
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2006
- Primary completion
- Feb 28, 2011
- Completion
- Feb 28, 2011
- Last update posted
- Apr 5, 2012
2006 – 2011
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Wilshire Oncology Medical Group, Inc. | La Verne | California | 91750 | — |
| Medical Oncology & Hematology | Waterbury | Connecticut | 06708 | — |
| Advanced Medical Specialties | Miami | Florida | 33176 | — |
| Northeast Georgia Cancer Care | Athens | Georgia | 30607 | — |
| Augusta Oncology Associates, PC | Augusta | Georgia | 30901 | — |
| Northwest Georgia Oncology Centers, PC | Marietta | Georgia | 30060 | — |
| North Idaho Cancer Center | Coeur d'Alene | Idaho | 83814 | — |
| Oncology-Hematology Associates, P.A. | Clinton | Maryland | 20735 | — |
| Hematology Oncology Centers of the Northern Rockies, PC | Billings | Montana | 59101 | — |
| Arena Oncology Associates | Lake Success | New York | 11042 | — |
| Tri-County Hematology and Oncology Associates | Canton | Ohio | 44718 | — |
| Mid Ohio Oncology/Hematology, Inc. | Columbus | Ohio | 43215 | — |
| Lancaster Cancer Center, Ltd. | Lancaster | Pennsylvania | 17605 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
| Cancer Specialists of Tidewater, Ltd. | Chesapeake | Virginia | 23320 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00366106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2012 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00366106 live on ClinicalTrials.gov.